腾讯网15 天
基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床 ...
智通财经APP讯，基石药业-B(02616)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动 ...
腾讯网15 天
基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期临床试验 ...
格隆汇3月4日丨基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推 ...
腾讯网15 天
基石药业-B(02616.HK)：CS2009全球多中心I期临床试验顺利完成首例患者给药
【财华社讯】基石药业-B(02616.HK)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应 ...
Nature22 年
VEGF and the quest for tumour angiogenesis factors
The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...
来自MSN2 个月
Researchers find association between elevated levels of protein VEGF-B and impaired kidney ...
A recently published study by Ulf Eriksson's research group at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet shows that elevated levels of the protein VEGF-B in ...
Nature4 个月
Biopanning and rapid analysis of selective interactive ligands
As a proof-of-principle, we screened human endothelial cells stimulated with vascular endothelial growth factor (VEGF) and constructed a peptide-based ligand-receptor map of the VEGF family.
Ophthalmology Times7 天
Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular ...
Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...